Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: An open, nonrandomized, parallel-group trial

Clinical Endocrinology

Volumn 67, Issue 5, 2007, Pages 776-783

  Langbakke, Irene H ^a   Nielsen, Jakob N ^a   Skettrup, Mia P ^a   Harper, Angela ^a   Klitgaard, Thomas ^a   Weil, Angelika ^b   Engelhardt, Eva ^b   Lange, Martin ^c  

^a NOVO NORDISK A S   (Denmark)

^b APEX Research   (Germany)

^c NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE BINDING PROTEIN; HUMAN GROWTH HORMONE; SIMPLEXX; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; MALE; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEADY STATE; VOMITING;

ADULT; AGED; AREA UNDER CURVE; CARRIER PROTEINS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS;

EID: 35448986543     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02962.x     Document Type: Article

References (40)

1. Pupim, L.B., Cuppari, L. Ikizler, T.A. (2006) Nutrition and metabolism in kidney disease. Seminars in Nephrology, 26, 134 157.
2. Kalantar-Zadeh, K. (2005) Recent advances in understanding the malnutrition- inflammation-cachexia syndrome in chronic kidney disease patients: What is next? Seminars in Dialysis, 18, 365 369.
3. Burrowes, J.D., Larive, B., Chertow, G.M., Cockram, D.B., Dwyer, J.T., Greene, T., Kusek, J.W., Leung, J. Rocco, M.V. (2005) Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the hemodialysis (HEMO) study. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association, 20, 2765 2774.
4. Pupim, L.B. Ikizler, T.A. (2003) Uremic malnutrition: new insights into an old problem. Seminars in Dialysis, 16, 224 232.
5. Kalantar-Zadeh, K., Kopple, J.D., Block, G. Humphreys, M.H. (2001) A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. American Journal of Kidney Diseases, 38, 1251 1263.
6. Mehrotra, R. Kopple, J.D. (2001) Nutritional management of maintenance dialysis patients: why aren't we doing better? Annual Review of Nutrition, 21, 343 379.
7. Ikizler, T.A., Wingard, R.L., Harvell, J., Shyr, Y. Hakim, R.M. (1999) Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney International, 55, 1945 1951.
8. Ikizler, T.A. Hakim, R.M. (1996) Nutrition in end-stage renal disease. Kidney International, 50, 343 357.
9. Lowrie, E.G. Lew, N.L. (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Diseases, 15, 458 482.
10. Bossola, M., Muscaritoli, M., Tazza, L., Giungi, S., Tortorelli, A., Fanelli, F.R. Luciani, G. (2005) Malnutrition in hemodialysis patients. What therapy? American Journal of Kidney Diseases, 46, 371 386.
11. Kalantar-Zadeh, K., Block, G., McAllister, C.J., Humphreys, M.H. Kopple, J.D. (2004) Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. American Journal of Clinical Nutrition, 80, 299 307.
12. Johannsson, G. Ahlmen, J. (2003) End-stage renal disease: endocrine aspects of treatment. Growth Hormone and IGF Research, 13 (Suppl. A S94 S101.
13. Iglesias, P., Diez, J., Fernandez-Reyes, M.J., Aguilera, A., Burgues, S., Martinez-Ara, J., Miguel, J.L., Gomez-Pan, A. Selgas, R. (1998) Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. American Journal of Kidney Diseases, 32, 454 463.
14. Johannsson, G., Bengtsson, B.A. Ahlmen, J. (1999) Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. American Journal of Kidney Diseases, 33, 709 717.
15. Jensen, P.B., Hansen, T.B., Frystyk, J., Ladefoged, S.D., Pedersen, F.B. Christiansen, J.S. (1999) Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone. Clinical Nephrology, 52, 103 109.
16. Hansen, T.B., Gram, J., Jensen, P.B., Kristiansen, J.H., Ekelund, B., Christiansen, J.S. Pedersen, F.B. (2000) Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis: a double-blind, randomized, placebo-controlled study. Clinical Nephrology, 53, 99 9107.
17. Garibotto, G., Barreca, A., Russo, R., Sofia, A., Araghi, P., Cesarone, A., Malaspina, M., Fiorini, F., Minuto, F. Tizianello, A. (1997) Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. Journal of Clinical Investigation, 99, 97 105.
18. Pupim, L.B., Flakoll, P.J., Yu, C. Ikizler, T.A. (2005) Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. American Journal of Clinical Nutrition, 82, 1235 1243.
19. Sohmiya, M., Ishikawa, K. Kato, Y. (1998) Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure. European Journal of Endocrinology/European Federation of Endocrine Societies, 138, 302 306.
20. Kotzmann, H., Yilmaz, N., Lercher, P., Riedl, M., Schmidt, A., Schuster, E., Kreuzer, S., Geyer, G., Frisch, H., Horl, W.H., Mayer, G. Luger, A. (2001) Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney International, 60, 1578 1585.
21. Feldt-Rasmussen, B., Lange, M., Sulowicz, W., Gafter, U., Lai, K.N., Wiedemann, J., Christiansen, J.S. El Nahas, M. (2007) Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. Journal of American Society of Nephrology, 18, 2161 2171.
22. Ericsson, F., Filho, J.C. Lindgren, B.F. (2004) Growth hormone treatment in hemodialysis patients - a randomized, double-blind, placebo-controlled study. Scandinavian Journal of Urology and Nephrology, 38, 340 347.
23. Haffner, D., Schaefer, F., Girard, J., Ritz, E. Mehls, O. (1994) Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. Journal of Clinical Investigation, 93, 1163 1171.
24. Schaefer, F., Baumann, G., Haffner, D., Faunt, L.M., Johnson, M.L., Mercado, M., Ritz, E., Mehls, O. Veldhuis, J.D. (1996) Multifactorial control of the elimination kinetics of unbound (free) growth hormone (GH) in the human: regulation by age, adiposity, renal function, and steady state concentrations of GH in plasma. Journal of Clinical Endocrinology and Metabolism, 81, 22 31.
25. Garcia-Mayor, R.V., Perez, A.J., Gandara, A., Andrade, A., Mallo, F. Casanueva, F.F. (1993) Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects. Clinical Endocrinology, 39, 337 343.
26. Food Drug Administration 1999) Guidance for Industry: Population Pharmacokinetics. US Department of Health and Human Services. Available at: http://www.fda.gov/cder/guidance/1852fnl.pdf (accessed 26 June 2007)
27. World Medical Association Declaration of Helsinki 2000) Ethical principles for medical research involving human subjects. Journal of the American Medical Association, 284, 3043 3045.
28. International Conference on Harmonisation 1996) ICH Harmonised Tripartite Guideline for Good Clinical Practice. Geneva, Switzerland. Available at: (accessed 26 June 2007)
29. Jacobsen, L.V., Rolan, P., Christensen, M.S., Knudsen, K.M. Rasmussen, M.H. (2000) Bioequivalence between ready-to-use recombinant human growth hormone (rhGH) in liquid formulation and rhGH for reconstitution: growth hormone and IGF research. Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 10, 93 98.
30. de, M., Klinger, J., Kefer, G., King, T. Harrison, F. (2001) Pharmacokinetics of human growth hormone administered subcutaneously with two different injection systems. Arzneimittelforschung, 51, 613 617.
31. Agersø, H., Møller-Pedersen, J., Cappi, S., Thomann, P., Jesussek, B. Senderovitz, T. (2002) Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. Journal of Clinical Pharmacology, 42, 1262 1268.
32. Boxenbaum, H. (1998) Pharmacokinetics tricks and traps: flip-flop models. Journal of Pharmacy and Pharmaceutical Sciences, 1, 90 91.
33. Catalina, P.F., Andrade, M.A., Garcia-Mayor, R.V. Mallo, F. (2002) Altered GH elimination kinetics in type 1 diabetes mellitus can explain the elevation in circulating levels: bicompartmental approach. Journal of Clinical Endocrinology and Metabolism, 87, 1785 1790.
34. Growth Hormone Research Society 2001) Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. Journal of Clinical Endocrinology and Metabolism, 86, 1868 1870.
35. Park, P. Cohen, P. (2004) The role of insulin-like growth factor I monitoring in growth hormone-treated children. Hormone Research, 62, 59 62.
36. Lee, P.D., Hintz, R.L., Sperry, J.B., Baxter, R.C. Powell, D.R. (1989) IGF binding proteins in growth-retarded children with chronic renal failure. Pediatrics Research, 26, 308 315.
37. Blum, W.F., Ranke, M.B., Kietzmann, K., Tonshoff, B. Mehls, O. (1991) Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatrics Nephrology, 5, 539 544.
38. Maheshwari, H.G., Rifkin, I., Butler, J. Norman, M. (1992) Growth hormone binding protein in patients with renal failure. Acta Endocrinologica (Copenh), 127, 485 488.
39. Hansen, T.K., Gravholt, C.H., Ørskov, H., Rasmussen, M.H., Christiansen, J.S. Jørgensen, J.O. (2002) Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. Journal of Clinical Endocrinology and Metabolism, 87, 4691 4698.
40. Catalina, P.F., Paramo, C., Andrade, M.A. Mallo, F. (2007) Growth hormone distribution kinetics are markedly reduced in adults with growth hormone deficiency. Clinical Endocrinology, 66, 341 347.